Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. - Wikidata - wikimedia - TriplyDB

Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.

Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.

http://www.wikidata.org/entity/Q37698956

about

Tumor angiogenesis: pericytes and maturation are not to be ignored Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Bevacizumab for glioblastoma Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Hypertension in patients with cancer Practical management of bevacizumab-related toxicities in glioblastoma Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs Proteins from Avastin® (bevacizumab) show tyrosine nitrations for which the consequences are completely unclear Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Antiangiogenic therapy of brain tumors: the role of bevacizumab.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.Risks and benefits with bevacizumab: evidence and clinical implications.Cancer, physical activity, and exercise Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.Role of reactive oxygen species during hypertension in response to chronic antiangiogenic factor (sFlt-1) excess in pregnant rats.SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice.Surgical, interventional, and device innovations in the management of hypertension Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies Current intravitreal pharmacologic therapies for diabetic macular edema.Cardiotoxicity of molecularly targeted agents Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1 Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience.Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy.Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review.Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?Incidence of new-onset hypertension in cancer patients: a retrospective cohort study.Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.Systemic therapies for metastatic renal cell carcinoma in older adults.Bevacizumab-induced hypertension: pathogenesis and management.Trials of bevacizumab in breast cancer--a safety review.Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.

P2860

Q21296683-47505FBF-A194-48B0-9D12-F6F8556B4A12 Q26752752-C5C52BA9-D32D-4D58-8BF6-4F2473BD5640 Q26776307-4EA99705-E0AB-493C-B8F4-674A57F27C68 Q26786618-092E41DB-FC20-44DE-8E2A-3925A0A8071C Q26859144-C4157A27-D9D4-4200-A696-8CF46F80624E Q27003980-F31228FE-4228-425E-82A7-F18CF426C37C Q27015852-2B77F04F-12D0-4B1C-B44E-ABAE756FC1CA Q28070311-1231948A-8472-489D-A5A7-8CC1F0C132DD Q28482364-0F1A1F7E-DCB0-4BB5-A926-244E83596E12 Q30417015-79D5EBB1-0E9D-433F-845C-3C49A2FF54AD Q30616602-3640FEDD-C514-4180-B5F7-A4B2700D7C41 Q30737224-BA2FEFC0-B36C-46FE-8531-E417BB2546A2 Q31060162-B2147F53-3848-4C7C-9557-7C29CB92D49B Q33904867-E62DD5DF-70D3-45BA-AF84-09CC31638318 Q33949406-69A3B4F3-F2C2-45B5-BDD6-BBF73AF2A406 Q34004946-F0F01FEB-81AF-490B-84CF-DC77DFDF569A Q34627959-42CE890D-012F-4D03-BE5E-7A023D699239 Q34724614-9E24D3CD-242E-4587-AA0D-8F4EB0301B12 Q35086662-610FD3BE-3E4B-4F3E-94C6-04521D9272B0 Q35121861-453DD8B9-5B2B-46E2-A82F-20151D13102E Q35141548-717C8E1A-C241-466F-9601-66F5EFD4B3C9 Q35584182-7EBDCD4E-3DC8-474C-8703-892D537E5BF0 Q35650268-E3FCDF59-308C-4343-B0C0-9CA0AF34460F Q35878459-EBF6100A-C9F2-4F2E-BFC4-BD09430F9F64 Q36008274-F404A750-2D76-4A51-8C8E-BE5CFC0E2332 Q36061770-018F0C48-3336-40CE-8CDF-8FCACA5ADD4B Q36627125-F94FE5DD-C016-4E73-9B71-9D46275CD327 Q36640122-1B64E74A-6269-455F-937A-32A737A7215F Q36649162-A0245C78-82A4-4465-AF92-B1D7221AD2DD Q36676062-C446EFC0-14C5-48BB-858B-C6940A860A44 Q36729895-A1DB2F14-0B0C-412D-8A78-48D18D60F81F Q36807321-888B1320-FE2B-4A87-A3C6-8E4E1DDBD7C7 Q37042424-F6AC9DA9-649F-4BE2-AF45-A33590E68933 Q37215966-5AEF1BDF-6F35-47A6-8E79-97981C9403F4 Q37422797-1E96531A-CCD8-4024-A682-B518C1A03656 Q37573849-F2816147-6AAA-457B-919D-404EEB65F831 Q37677105-93414A09-A547-4BCB-9133-8AC8C6C1FD77 Q37882684-0CD22F86-5D67-4AB2-98F0-FC5A569F09E5 Q37887823-8F26CFCA-DA73-4FE0-A7C2-5D5AEEA78038 Q37926954-C5DDD9D8-2D34-4C46-835C-69D47B76DA39

P2860

Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.

http://www.wikidata.org/entity/Q37698956

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 February 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Increased risk of high-grade h ...... cer patients: a meta-analysis.

@en

Increased risk of high-grade h ...... cer patients: a meta-analysis.

@nl

type

label

Increased risk of high-grade h ...... cer patients: a meta-analysis.

@en

Increased risk of high-grade h ...... cer patients: a meta-analysis.

@nl

prefLabel

Increased risk of high-grade h ...... cer patients: a meta-analysis.

@en

Increased risk of high-grade h ...... cer patients: a meta-analysis.

@nl

P1433

Q37698956-F9061B19-D552-4FDC-ABFF-7B70EB6921D7

P1476

Q37698956-7D231B73-845B-4963-823E-A4929BC67F53

P2093

Q37698956-3E87FF75-9D33-45B7-AB77-91584D91E1BD

Q37698956-534A1696-058D-452D-9C30-4DDF96BD18B6

Q37698956-79A8695E-1F24-4A8B-8483-FD852B8F8D46

Q37698956-89D40AC9-942F-4CFC-9711-95BCA708191B

Q37698956-93913C60-E7C0-4A28-9DEC-96C1DFAD4E5C

P2860

Q37698956-0F539D4F-19A7-4014-8BA6-D65FD72C6A35

Q37698956-14E01E82-709E-44C6-9954-1B17F199993B

Q37698956-29947F37-0007-46D4-8969-6E2DF98896EC

Q37698956-2AA8ED68-9AD0-444B-9AA7-10F43EAB4F7F

Q37698956-2CDDB04F-94C9-4E8A-A4F8-1FDBA1FA7F1B

Q37698956-2D6CDE35-D4ED-47E4-AEFA-F7836A36BBEE

Q37698956-2ED4DC77-905B-41F5-A3A9-E0235C86319A

Q37698956-34949511-583B-478E-91C3-2613B832C390

Q37698956-560E31B1-0AE2-451F-9633-07EBA5587653

Q37698956-67C3A859-DEFD-477A-A52D-39DC54A20FBA

P304

Q37698956-F5E5E1E1-0C9A-429D-B40A-BBF3A0767BD6

P31

Q37698956-0EBE2E7E-0F98-48BF-9C19-1CE8DE765EB1

Q37698956-f585b6ef-1f67-460f-ade1-4f1ddb3811b5

P356

Q37698956-02AEC204-E3DD-4707-AD03-A334B49D4988

P433

Q37698956-8E0A71A1-F614-4464-80CD-08965EB3C69B

P478

Q37698956-06083AE2-1B5A-4247-94B0-ACABA159D104

P577

Q37698956-9C006653-CF08-4977-B70E-5D19A0986E8E

P698

Q37698956-02F5AB74-02CA-480D-A4B3-983A9C01BCA5

P921

Q37698956-95F64CA5-FDDE-419B-BF10-D4CB21F39317

Q37698956-C33F973C-38D3-4A5B-A69C-80E9E83D3FD4

Q37698956-DCD8282E-61AF-4A66-AF9E-B0009A2D30A3

Q37698956-F1CAE93E-BFBD-4D81-806F-A4B7B7164215

P356

P1433

American Journal of Hypertension

P1476

Increased risk of high-grade h ...... cer patients: a meta-analysis.

@en

P2093

Bhargava Pulipati

http://www.w3.org/2001/XMLSchema#string

David Chu

http://www.w3.org/2001/XMLSchema#string

Shenhong Wu

http://www.w3.org/2001/XMLSchema#string

Vishal Ranpura

http://www.w3.org/2001/XMLSchema#string

Xiaolei Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Operating characteristics of a rank correlation test for publication bias

Quantifying heterogeneity in a meta-analysis

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Meta-analysis in clinical trials

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Role of angiogenesis in tumor growth and metastasis

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.

P304

460-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJH.2010.25

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20186127

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension